Phase II Study of Grass Pollen Allergy Vaccine BM32

PHASE2CompletedINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

March 31, 2015

Conditions
Grass Pollen Allergy
Interventions
BIOLOGICAL

BM32

Subcutaneous injection of 20 micrograms of each of the protein components of BM32 adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season

BIOLOGICAL

BM32

Subcutaneous injection of 40 micrograms of each of the protein components of BM32 adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season

BIOLOGICAL

Placebo

Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every four weeks before each pollen season and one injection after pollen season for a total of 7 injections

Trial Locations (11)

1090

Medical University, Vienna

3105

Dept. of Internal Medicine Erasmus Medical Center, Rotterdam

4204

University Clinic of Respiratory and Allergic Diseases Golnik, Golnik

8036

Universitätsklinik für Dermatologie und Allergologie, Graz

9000

Allergy Network Ghent University Hospital Ghent, Dept. Otorhiolaryngologie, Ghent

10117

Allergiezentrum Charite, Berlin

35043

Dept. of Dermatology and Allergology University Medical Center Gieseen and Mrbaurg GmbH, Marburg

53105

Klinik und Poliklnik für Dermatologie und Allergologie der Universität Bonn, Bonn

65183

Zentrum für Rhinologie/Allergologie, Wiesbaden

80802

Department of Dermatology and Allergology Am Biederstein TU Munich, Munich

Unknown

Allergy Clinic Copenhagen University Hospital at Gentofte, Hellerup

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biomay AG

INDUSTRY

NCT01538979 - Phase II Study of Grass Pollen Allergy Vaccine BM32 | Biotech Hunter | Biotech Hunter